Get the Stockscreener App
6.45
4.59%
-0.31
After Hours:
6.71
0.26
+4.03%
Coya Therapeutics Inc stock is traded at $6.45, with a volume of 46,820.
It is down -4.59% in the last 24 hours and up +6.97% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$6.76
Open:
$6.75
24h Volume:
46,820
Relative Volume:
1.08
Market Cap:
$102.21M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-4.8624
EPS:
-1.3265
Net Cash Flow:
$-11.39M
1W Performance:
+9.88%
1M Performance:
+6.97%
6M Performance:
-34.98%
1Y Performance:
+67.97%
1-Day Range:
$6.40
$7.20
1-Week Range:
$5.87
$7.20
52-Week Range:
$3.21
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Coya Therapeutics Inc Stock (COYA) Latest News
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 7.3% in September - MarketBeat
(COYA) Proactive Strategies - Stock Traders Daily
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coty Inc. (NYSE:COTY) Shares Sold by Thrivent Financial for Lutherans - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Rhumbline Advisers - Defense World
MQS Management LLC Sells 18,446 Shares of Coty Inc. (NYSE:COTY) - Defense World
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World
COYA 302 combination therapy tames brain inflammation in mice - Parkinson's News Today
HC Wainwright Comments on Coya Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:COYA) - MarketBeat
Play it back: Houston therapeutics co. sees momentum with expanded treatment opportunities - InnovationMap
CorriXR Therapeutics Appoints Jill Castilla to Its Board of Directors - Business Wire
Coya Therapeutics reports potential Parkinson's treatment breakthrough - Investing.com
Coya Therapeutics reports potential Parkinson's treatment breakthrough - Investing.com India
Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright - MarketBeat
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease - StockTitan
HC Wainwright & Co. Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update - MarketBeat
Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation - Yahoo Finance
Coya Therapeutics to Present at Upcoming Healthcare Conferences - StockTitan
Coya Therapeutics promotes Arun Swaminathan to CEO post - The Pharma Letter
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics appoints new CEO, founder shifts role - Investing.com
Coya Therapeutics Names Arun Swaminathan Chief Executive - MarketWatch
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - Manchestertimes
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) to Post FY2024 Earnings of ($1.17) Per Share, Chardan Capital Forecasts - MarketBeat
Vanguard Group Inc. Has $8.41 Million Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Vanguard Group Inc. - Defense World
Coya Therapeutics, Inc. (NASDAQ:COYA) Forecasted to Earn FY2025 Earnings of ($1.26) Per Share - MarketBeat
Chardan Capital Weighs in on Coya Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:COYA) - Defense World
Frontotemporal Dementia Market to Show Remarkable Growth - openPR
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - Manchestertimes
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - wallstreet:online
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - Defense World
Coya Therapeutics Blunders on Test Results - MSN
Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com India
Coya reports Alzheimer's trial to present at CTAD24 - Investing.com
Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com Canada
Coya Therapeutics Blunders on Test Results - Baystreet.ca
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid - Chronicle-Tribune
Coya Therapeutics files for IP on novel therapy combination - Investing.com
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - StockTitan
Long Term Trading Analysis for (COYA) - Stock Traders Daily
(COYA) Investment Report - Stock Traders Daily
Coya Shares Rise After Next Step to New Study of ALS Treatment - MarketWatch
Coya Therapeutics faces FDA hold on ALS drug study - Investing.com
individual investors who own 58% along with institutions invested in Coya Therapeutics, Inc. (NASDAQ:COYA) saw increase in their holdings value last week - Simply Wall St
Coya Therapeutics faces FDA hold on ALS drug study By Investing.com - Investing.com Canada
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):